Earnings Announcement Next Earnings date is expected on 10/22/2019
Last Price$226.06NASDAQ Closing Price as of 4:00PM ET 10/15/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.30(0.13%)
Bid (Size)$223.00 (1)
Ask (Size)$226.28 (4)
Day Low / High$225.16 - 228.33
Volume2.0 M

View Biotechnology IndustryPeer Comparison as of 10/15/2019


Biogen Inc ( NASDAQ )

Price: $226.06
Change: +0.30 (0.13%)
Volume: 2.0 M
4:00PM ET 10/15/2019

Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $176.15
Change: +2.56 (1.47%)
Volume: 742.7 K
4:00PM ET 10/15/2019

Illumina Inc ( NASDAQ )

Price: $312.17
Change: +1.86 (0.60%)
Volume: 621.7 K
4:00PM ET 10/15/2019

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $303.82
Change: -1.62 (0.53%)
Volume: 735.3 K
3:59PM ET 10/15/2019

Agilent Technologies Inc ( NYSE )

Price: $75.75
Change: +0.57 (0.76%)
Volume: 854.7 K
4:10PM ET 10/15/2019

Read more news Recent News

--Analyst Actions: Wedbush Cuts Price Target on Biogen to $218 From $233, Maintains Neutral Rating
8:11AM ET 10/14/2019 MT Newswires

Price: 223.21, Change: +0.21, Percent Change: +0.09 ...

Analyst Actions: Morgan Stanley Lifts Biogen's Price Target to $212 From $211, Keeps Underweight Rating
11:02AM ET 10/11/2019 MT Newswires

Biogen (BIIB) has an average rating among analysts of hold, with an average price target of $270. Price: 225.73, Change: +2.73, Percent Change: +1.22 ...

Biogen Says No Infants Died in Study of Treatment for Spinal Muscular Atrophy
9:50AM ET 10/02/2019 MT Newswires

Biogen (BIIB) on Wednesday reported that its NURTURE study, which evaluates the treatment with Spinraza for the underlying cause of spinal muscular atrophy...

Biogen Widens Chief Medical Officer Alfred Sandrock's Responsibilities With R&D Role
10:08AM ET 10/01/2019 MT Newswires

Biogen (BIIB) said Tuesday Chief Medical Officer Alfred Sandrock, Jr., has been named executive vice-president of research and development. This comes as...

View all Commentary and Analysis

Healthcare And Biotechnology Dashboard - Update
11:00AM ET 10/14/2019 Seeking Alpha

IPO Update: Vir Biotechnology Proposes IPO Terms
7:00PM ET 10/01/2019 Seeking Alpha

New Biogen Spinraza Trial Has Little To Do With Novartis Competition
9:08AM ET 9/25/2019 Seeking Alpha

Healthcare And Biotechnology Dashboard - Update
2:10AM ET 9/18/2019 Seeking Alpha

Company Profile

Business DescriptionBiogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. View company web site for more details
Address225 Binney Street
Cambridge, Massachusetts 02142
Number of Employees7,800
Recent SEC Filing10/01/20198-K
Chief Executive Officer & DirectorMichel Vounatsos
Chief Financial Officer & Executive Vice PresidentJeffrey D. Capello
Chief Medical Officer & EVP-Research & DevelopmentAlfred W. Sandrock
Chief Information Officer & Senior Vice PresidentMark Hernon

Company Highlights

Price Open$225.41
Previous Close$225.76
52 Week Range$215.78 - 344.00
Market Capitalization$41.7 B
Shares Outstanding184.4 M
SectorHealth Technology
Next Earnings Announcement10/22/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings8.30
Earnings per Share$28.62
Beta vs. S&P 500N/A
Revenue$12.1 B
Net Profit Margin42.27%
Return on Equity39.52%

Analyst Ratings as of 10/10/2019

Consensus RecommendationConsensus Icon
Powered by Factset